ライフサイエンスコーパス: mucosal healing

1 improving anabolic metabolism and enhancing mucosal healing.

2 reased susceptibility to injury and impaired mucosal healing.

3 ithelial differentiation, proliferation, and mucosal healing.

4 ion and for the sheet migration required for mucosal healing.

5 lamed CD tissue and can lead to dysregulated mucosal healing.

6 patients and often does not lead to complete mucosal healing.

7 reliable as endoscopy for the assessment of mucosal healing.

8 sed this genomic instability and accelerated mucosal healing.

9 patients with CeD, as well as patients with mucosal healing.

10 epitopes can identify patients with CeD with mucosal healing.

11 healing vs patients with asymptomatic IBD in mucosal healing.

12 at epithelial TNFR signaling participates in mucosal healing.

13 ammatory bowel diseases (IBD) and intestinal mucosal healing.

14 to mice with induced colonic wounds promoted mucosal healing.

15 mptoms of diarrhea or abdominal pain despite mucosal healing.

16 0.81 for endoscopic remission, and 0.78 for mucosal healing.

17 hn's disease (CD) is reflected in intestinal mucosal healing.

18 atric patients with IBD suggesting a role in mucosal healing.

19 examined, negative EMA most reliably predict mucosal healing.

20 hibition of enterocyte migration and reduced mucosal healing.

21 e treated with pantoprazole until esophageal mucosal healing.

22 ssue injury while improving wound repair and mucosal healing.

23 ; endoscopic remission, 44 vs 489 mg/kg; and mucosal healing, 127 vs 753 mg/kg.

24 re present in 16.3% of patients with IBD and mucosal healing (15.4% of patients with CD, 17.4% with U

25 golimumab were in clinical remission and had mucosal healing (27.8% and 42.4%) than patients given pl

26 Although previously linked to mucosal healing(4), we now implicate pyloric gland metap

27 %) achieved clinical remission (P < .05) and mucosal healing (41% GZMA(high) vs 19% GZMA(low) and 44%

28 owever, out of 12 EMA-positive children with mucosal healing, 9 subsequently turned EMA-negative.

29 stablished CD, CE plays a role in monitoring mucosal healing, a key therapeutic target linked to impr

30 cations for a novel therapeutic approach for mucosal healing, a significant unmet need in IBD treatme

31 CERTIN: a recombinant CTB variant possessing mucosal healing activity.

32 e involved in the development of colitis and mucosal healing after colonic inflammation.

33 1% of patients (56/92) with histo-endoscopic mucosal healing after induction therapy achieved clinica

34 ndicated the achievement of histo-endoscopic mucosal healing after induction therapy is associated wi

35 , often leading to detrimental side effects, mucosal healing agents that target the gut epithelium ar

36 ustained epithelial cell apoptosis precluded mucosal healing and decreased animal survival.

37 nt that treatment targets in IBD will ensure mucosal healing and deep remission.

38 Mice lacking ITF had impaired mucosal healing and died from extensive colitis after or

39 In patients with CD, mucosal healing and endoscopic response (defined as a de

40 At week 26, mucosal healing and endoscopic response were achieved in

41 kers of sustained small intestinal growth or mucosal healing and evaluation of intestinal epithelial

42 egulated inflammation is intrinsic to normal mucosal healing and homeostasis, but prolonged OE inflam

43 the elderly, namely differential diagnosis, mucosal healing and IBD-associated dysplasia.

44 ate-induced colitis in mice, associated with mucosal healing and immunomodulation.

45 ive bacteria; produced metabolites promoting mucosal healing and immunoregulatory responses; decrease

46 Inhibiting serine synthesis impaired colonic mucosal healing and increased susceptibility to acute in

47 group 3 innate lymphoid cells (ILC3) promote mucosal healing and maintain barrier integrity, but how

48 cifically promote epithelial restitution and mucosal healing and may be useful to treat gut mucosal i

49 ications as they provide clinical remission, mucosal healing and prevent extra-intestinal manifestati

50 ications as they provide clinical remission, mucosal healing and prevent extra-intestinal manifestati

51 ith colitis given anti-TNF had near complete mucosal healing and Rag1(-/-) mice given an isotype cont

52 velopment of novel therapeutics that promote mucosal healing and reestablish the critical epithelial

53 epithelial homeostasis and the promotion of mucosal healing and suggest that recombinant MFG-E8 may

54 aling may represent a novel means to promote mucosal healing and to maintain intestinal homeostasis a

55 s of remission, therapeutic goals (including mucosal healing) and outcomes that matter to patients, s

56 er, the molecular integration among colitis, mucosal healing, and CAC remains poorly understood.

57 y higher in patients with clinical response, mucosal healing, and/or clinical remission than in patie

58 In patients with ulcerative colitis, mucosal healing appears to be an important predictor of

59 In patients with Crohn's disease, mucosal healing appears to predict future endoscopic act

60 While the processes of mucosal healing are well studied, how neutrophils advanc

61 he literature concerning the significance of mucosal healing as a predictor of future clinical and en

62 activity index, and inclusion of endoscopic mucosal healing as the remission definition all were ass

63 y end points included clinical remission and mucosal healing at both weeks 30 and 54.

64 percent of patients receiving adalimumab had mucosal healing at week 12 (the primary end point) versu

65 Mucosal healing at week 16 occurred in 62.8% (49 of 78)

66 Mucosal healing at week 26 was associated with CFREM at

67 100 mg golimumab had clinical remission and mucosal healing at weeks 30 and 54.

68 our peptide panel to identify patients with mucosal healing (based on the histologic analysis) using

69 able for monitoring treatment response, with mucosal healing being a major treatment goal.

70 of IECs in mice with colitis and accelerates mucosal healing by activating STAT1.

71 ical fibroblast subpopulation that expedites mucosal healing by facilitating early immune response.

72 atrophy was compared with that of those with mucosal healing by using Cox regression.

73 The primary endpoint was mucosal healing (CDEIS <4) with absence of deep ulcers 4

74 Key secondary end points were response and mucosal healing (centrally read) at week 8.

75 10% to 20% higher rates of histo-endoscopic mucosal healing, clinical remission, and corticosteroid-

76 The percentages of patients with mucosal healing, clinical response, clinical remission a

77 At week 52, rates of mucosal healing (composite end point of histologic plus

78 possibly novel role of CLDN2 in promotion of mucosal healing downstream of EGFR signaling and by regu

79 increased CCN1 expression may be involved in mucosal healing during colitis.

80 (NK-1R), both in vitro and in vivo, promote mucosal healing during recovery from colitis by stimulat

81 of defense systems and factors that enhance mucosal healing, focusing on findings that elucidate new

82 gut epithelial surface, where they stimulate mucosal healing following acute injury.

83 apy in achieving optimal growth and inducing mucosal healing for pediatric Crohn's disease.

84 persistent clinical disease activity despite mucosal healing has been observed in clinical practice a

85 n this cutoff, 36.2% of patients with IBD in mucosal healing have increased intestinal permeability.

86 adalimumab for induction and maintenance of mucosal healing in 135 adults with moderate to severe il

87 Exogenous KGF has a key role in mucosal healing in an experimental model of colitis in r

88 apoptosis may be an important mechanism for mucosal healing in anti-TNF-treated CUC patients.

89 uR deficiency in the pathogenesis of delayed mucosal healing in certain pathological conditions.

90 ormone reduces disease activity and promotes mucosal healing in colitis and can activate SHP-2.

91 Impaired mucosal healing in double IFN receptor-deficient mice is

92 (<= 679 ug/g) were significant predictors of mucosal healing in familial cases (P = 0.012, P = 0.008,

93 ells could reveal novel approaches to direct mucosal healing in inflammation and disease.

94 lay an important role in gut homeostasis and mucosal healing in inflammatory bowel disease.

95 igration, whereas deletion of MFG-E8 impeded mucosal healing in mice with sepsis.

96 (FAK) activator, M64HCl, promotes intestinal mucosal healing in mice.

97 y of adalimumab for inducing and maintaining mucosal healing in patients with Crohn's disease (CD).

98 entially novel role of CLDN2 in promotion of mucosal healing in patients with IBD and thus regulation

99 ks induced remission, clinical response, and mucosal healing in patients with moderate-to-severe ulce

100 nduced mitochondrial respiration may improve mucosal healing in patients with radiation injury.

101 tion may be an effective strategy to promote mucosal healing in patients with UC.

102 of MKP-1 might be the basis for the impaired mucosal healing in PHT gastric mucosa.

103 echanisms that control tissue protection and mucosal healing in response to intestinal damage remain

104 D1b receptor agonists might be used to help mucosal healing in the gastrointestinal tract.

105 athway whereby cDC-derived hepcidin promotes mucosal healing in the intestine through means of nutrit

106 apeutic applications for this SPM to promote mucosal healing in the intestine.

107 The proportion of patients with complete mucosal healing increased over time, with greater rates

108 Recent evidence suggests that mucosal healing is also an important predictor of long-t

109 Assessment of mucosal healing is an important tool in the management o

110 is effective, well tolerated and that early mucosal healing is associated with decreased risk of col

111 largely driven by immune cell activity, and mucosal healing is critical for remission.

112 surrogates of risk of disease complications; mucosal healing is the most valid endpoint used to deter

113 -up intestinal biopsy, performed to document mucosal healing, is unknown.

114 Because enterocytes migrate together, mucosal healing may require interenterocyte communicatio

115 Among group B children, 88.7% showed mucosal healing (median 2.2 years after primary diagnosi

116 Mucosal healing (MH) evaluated by endoscopy is a novel t

117 Mucosal healing might alter midterm and long-term outcom

118 Resolution of mucosal permeability beyond mucosal healing might improve outcomes of patients with

119 -up period of 1 year and was associated with mucosal healing observed in follow-up endoscopy.

120 After remission of SJS/TEN, a complete ENT mucosal healing occurred in 36 patients (74%) at 2 month

121 ures of inflammatory bowel disease, complete mucosal healing occurs in fewer than 50% of patients.

122 6 [95% credible interval, 1.22 to 4.63]) and mucosal healing (odds ratio, 2.02 [95% credible interval

123 orted outcomes and deep remission defined as mucosal healing on colonoscopy or imaging.

124 mast cell protease 4 did not restore normal mucosal healing or reduce efficiently inflammation after

125 t endpoint, which we called histo-endoscopic mucosal healing (or histo-endoscopic mucosal improvement

126 y responded (clinical remission and complete mucosal healing) or did not respond to infliximab.

127 Mucosal healing plays a critical role in combatting the

128 In contrast, mucosal healing predicts improved prognosis in IBD and r

129 Response and mucosal healing rates with these dosages also were signi

130 MCs were localized in areas of mucosal healing rather than damaged areas where they deg

131 Because ERK2 is crucial for mucosal healing, reduced ERK2 activation resulting from

132 e downstream processes by which TLR4 impairs mucosal healing remain incompletely understood.

133 GI mucosal healing requires epithelial sheet migration.

134 There was an inverse association between mucosal healing risk of future small bowel adenocarcinom

135 78 [CI, 2.71 to 5.12]) than among those with mucosal healing (SIR, 1.50 [CI, 0.77 to 2.62]).

136 Multiple factors affect oral mucosal healing, such as the persistence of an inflammat

137 bination therapy led to significantly better mucosal healing than azathioprine monotherapy.

138 eceive adalimumab are more likely to achieve mucosal healing than those given placebo.

139 clinical responses, clinical remissions, and mucosal healings than placebo for induction therapy.

140 d durable remission has been associated with mucosal healing, the recurrent phenomenon of persistent

141 Intestinal inflammation can impair mucosal healing, thereby establishing a vicious cycle le

142 The transcription factor KLF5 regulates mucosal healing through its effects on epithelial prolif

143 Mechanistically, D. hansenii impaired mucosal healing through the myeloid cell-specific type 1

144 ggest a physiologic role for TFF2 to promote mucosal healing through the stimulation of proliferation

145 eability in patients with symptomatic IBD in mucosal healing vs patients with asymptomatic IBD in muc

146 Mucosal healing was achieved in a greater percentage of

147 Persistent villous atrophy compared with mucosal healing was associated with an increased risk fo

148 Mucosal healing was defined as absence of ulcers.

149 Mucosal healing was defined as CD Endoscopic Index of Se

150 re </=2, with no individual subscore >1, and mucosal healing was defined as endoscopic score </=1.

151 Mucosal healing was evaluated by repeated injury surface

152 Mucosal healing was reassessed by ileocolonoscopy at wee

153 Mucosal healing was significantly more common among the

154 stinal permeability in patients with IBD and mucosal healing, we associated impaired intestinal perme

155 kinase (ERK) plays a pivotal role in gastric mucosal healing, we investigated whether ERK activation

156 At week 52, rates of mucosal healing were 24% and 0, respectively (P < .001).

157 Predictors of response and mucosal healing were assessed via logistic regression.

158 oing bowel symptoms in patients with IBD and mucosal healing with 95.2% sensitivity and 97.6% specifi

159 ving immunomodulators should be assessed for mucosal healing within 1 year of treatment initiation.

160 is treatment success at week 48, defined as mucosal healing without surgery or death.